335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22823 | Already received a prescription for vandeanib | Ahmad Hussein Awada | Thyroïd | AstraZeneca | NIS-OBE-CAP-2013/1 | Trial closed | Caprelsa(r) Registry : A Belgian Registry to evaluate the use of Vandetanib (Caprelsa(r)) in current clinical practice | ahmad.awada@hubruxelles.be | |||
| 22667 | First relapse or progression Agressive NHL Age > 65 YO or >18 yo and HCT-CI score > 2 or prior ASCT and not eligible for allogeneic transplantation |
Marie Maerevoet | Non-Hodgkin lymphoma | LYSA LYmphoma | NIVEAU - DSHNHL 2015-01 | Trial closed | Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma | marie.maerevoet@hubruxelles.be | 2/3 | 2 | |
| 22668 | second line metastatic | Thierry Berghmans | Thymus | EORTC | Nivothym | Trial closed for recruitment | Single-arm, multicenter, phase II study of nivolumab in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym) | 2 | 2 | ||
| 22980 | Prospective MGUS patients: IgG, IgA or light chain MGUS, as defined by the International Myeloma Working Group (IMWG) Updated Criteria for the Diagnosis of Multiple Myeloma ? Prospective SMM patients: IgG, IgA or light chain SMM, as defined by the IMWG Up |
Nathalie Meuleman | Myeloma | Janssen | NOPRODMMY0001 | Trial open for recruitment | Myeloma Progression Omics Profling (MPOP) : An Atlas of High-Content Single-Cell Immunophenotyping and Single Cell Transcriptomics in Myeloma and its Precursor States | nathalie.meuleman@hubruxelles.be | |||
| 29428 | Saude Conde Rita | Multiple | Oxford BioTherapeutics | OBT076-001 | Trial open for recruitment | A Phase I/Ib, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors. (OBT076-001) | 1/1b | 1 | |||
| 22689 | 2nd line metastatic, RECIST 1.1, HER2 negative, Hormono positive | Andrea Gombos | Breast | Odonate | ODO-TE-B301, CONTESSA | Trial closed | A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22616 | adjuvant, TNBC | Daphné t'Kint de Roodenbeke | Breast | AstraZeneca | OLYMPIA D081CC00006 BIG 6-13, NSABP B-55 | Trial closed for recruitment | A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OLYMPIA study) | daphne.tkint@hubruxelles.be | 3 | 3 | |
| 29648 | Pieter Demetter | Multiple | Bayer | ON-TRK: | Trial open for recruitment | PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib | pieter.demetter@hubruxelles.be | ||||
| 28638 | Saude Conde Rita | Esophagus | Innovent Biologics (Suzhou) Co., Ltd. | ORIENT-15 | Trial closed for recruitment | A Multicenter, Double-blind, Randomised Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-line Treatment of Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | 3 | 3 | |||
| 22723 | SIRP-alpha polymorphism V1/V1 or V1/V2 | Nuria Kotecki | Multiple | OSE Immunotherapeutics | OSE 172C101 | Trial closed | An open-label phase 1 dose finding study of BI 765063, a monoclonal antibody (mAb) antagonist of SIRPa, as single agent and in combination with BI 754091, a programmed death-1 (PD-1) mAb, to characterize safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 29429 | Nuria Kotecki | Multiple | OSE Immunotherapeutics | OSE-279-C101 | Trial open for recruitment | A multicenter, phase 1/2, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas (OSE-279-C101) | Nuria.Kotecki@hubruxelles.be | 1/2 | 1 | ||
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22727 | Advanced, recurrent, ou unresecable | Ahmad Hussein Awada | Lung | AstraZeneca | PACIFIC R | Trial closed for recruitment | First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy - PACIFIC Real World, PACIFIC-R | ahmad.awada@hubruxelles.be | 4 | 4 | |
| 22772 | ER+/PR+/HER2-. Adjuvant. Palbociclib | Michail Ignatiadis | Breast | ABCSG | PALLAS | Trial closed for recruitment | PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer | michail.ignatiadis@hubruxelles.be | 3 | 3 |